What additional share acquisition did the MapLight Therapeutics (MPLT) filing disclose for Jonathan Gillis?

The filing notes that Jonathan Gillis acquired 121 shares under MapLight Therapeutics’ stock purchase plan on March 31, 2026. These shares are included in his post-transaction holding of 251,054 shares of Voting Common Stock reported after the tax-related sale.

MapLight (MPLT) officer sells 3,590 shares to cover tax withholding

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics officer Jonathan Gillis, CAAO and PAO, sold 3,590 shares of Voting Common Stock in an open-market transaction at a weighted average price of $26.61 per share. According to the footnotes, these shares were sold solely to cover statutory tax withholding obligations tied to the vesting of restricted stock units.

After the sale, Gillis directly owned 251,054 shares, which includes 121 shares acquired under the company’s stock purchase plan on March 31, 2026. The sale price range for the transaction was between $26.6045 and $26.6093 per share.

Insider Trade Summary

Net Seller: 3,590 shares ($95,530)

Net Sell 1 txn

Insider GILLIS JONATHAN

Role CAAO and PAO

Sold 3,590 shs ($96K)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	3,590	$26.61	$96K

Holdings After Transaction: Voting Common Stock — 251,054 shares (Direct)

Footnotes (1)

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.6045 to $26.6093 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes 121 shares acquired under the Issuer's stock purchase plan on March 31, 2026.

Key Figures

Shares sold: 3,590 shares Weighted average sale price: $26.61 per share Sale price range: $26.6045–$26.6093 per share +2 more

5 metrics

Shares sold 3,590 shares Voting Common Stock sold on 2026-04-15 to cover tax withholding

Weighted average sale price $26.61 per share Open-market sale of 3,590 shares

Sale price range $26.6045–$26.6093 per share Multiple transactions within this range on 2026-04-15

Shares owned after transaction 251,054 shares Direct holdings of Voting Common Stock following the sale

Shares from stock purchase plan 121 shares Acquired under issuer’s stock purchase plan on March 31, 2026

Key Terms

statutory tax withholding obligations, restricted stock units, weighted average price, stock purchase plan, +1 more

5 terms

statutory tax withholding obligations financial

"shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting"

restricted stock units financial

"tax withholding obligations in connection with the vesting of the restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

stock purchase plan financial

"Includes 121 shares acquired under the Issuer's stock purchase plan on March 31, 2026"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

04/17/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILLIS JONATHAN

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CAAO and PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	04/15/2026		S		3,590⁽¹⁾	D	$26.61⁽²⁾	251,054⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.6045 to $26.6093 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes 121 shares acquired under the Issuer's stock purchase plan on March 31, 2026.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MapLight Therapeutics (MPLT) report for Jonathan Gillis?

MapLight Therapeutics reported that officer Jonathan Gillis sold 3,590 shares of Voting Common Stock. The transaction was an open-market sale used to cover statutory tax withholding obligations related to vesting restricted stock units, as described in the filing footnotes.

At what price did Jonathan Gillis sell MapLight Therapeutics (MPLT) shares?

Jonathan Gillis sold 3,590 shares at a weighted average price of $26.61 per share. The filing notes individual trades occurred in a narrow range between $26.6045 and $26.6093, and Gillis undertook to provide detailed breakdowns upon request.

Why were shares of MapLight Therapeutics (MPLT) sold by Jonathan Gillis?

The filing states the 3,590 shares sold by Jonathan Gillis were required to cover statutory tax withholding obligations. These obligations arose from the vesting of his restricted stock units, meaning the sale was tied to equity compensation taxes rather than a discretionary liquidation.

How many MapLight Therapeutics (MPLT) shares does Jonathan Gillis hold after this transaction?

Following the sale, Jonathan Gillis directly owned 251,054 shares of Voting Common Stock. This total includes 121 shares he acquired on March 31, 2026 under the company’s stock purchase plan, as disclosed in the filing’s footnotes.